Furthermore, BCR-ABL1 expression induces SET-mediated inactivation of PP2A, whose lost activity in CML can be reestablished by PP2A activating drugs FTY720 (14–17). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.